Dale VanderPutten, CEO of Omnia Biologics, said: “The team at Omnia is very pleased to have assisted Sumagen in this important effort addressing the new priorities of the path forward in the wake of the Step study. Sumagen, like many companies in the experimental biologics space, has had great difficulty in finding suitable contract manufacturing expertise to move their products into clinical trials.
“After the failure of other contract manufacturing organizations, we are happy that Omnia’s customer focused and product specialized services were able to satisfy 250% of their required yield on schedule.”